Massive haircut from a stop loss? I'm not sure why you were expecting revenue from the manufacture plant to be significant anyway, IMU's assets are their IP and the products are years away from approval. SH initially questioned this manufacture plan acquisition but noticed it was needed for registrational clinical trial of Azer-Cel to produce the drug which has also been secure with this partnership.
IMU's MC valuation will increase with significant clinical updates (last was 5 months ago) and then regulatory approval, these milestone will attract more Instos investment making the pps less volatile.
IMU Price at posting:
8.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)